Literature DB >> 25863751

Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Lena Specht1, Bouthaina Dabaja2, Tim Illidge3, Lynn D Wilson4, Richard T Hoppe5.   

Abstract

Primary cutaneous lymphomas are a heterogeneous group of diseases. They often remain localized, and they generally have a more indolent course and a better prognosis than lymphomas in other locations. They are highly radiosensitive, and radiation therapy is an important part of the treatment, either as the sole treatment or as part of a multimodality approach. Radiation therapy of primary cutaneous lymphomas requires the use of special techniques that form the focus of these guidelines. The International Lymphoma Radiation Oncology Group has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the International Lymphoma Radiation Oncology Group steering committee on the use of radiation therapy in primary cutaneous lymphomas in the modern era.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25863751     DOI: 10.1016/j.ijrobp.2015.01.008

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  ISRT: a new radiation therapy for malignant lymphomas: Introduction to the review article by Specht and Yahalom.

Authors:  Keisuke Sasai; Masahiko Oguchi
Journal:  Int J Clin Oncol       Date:  2015-07-11       Impact factor: 3.402

2.  The effectiveness of radiotherapy for leukemia cutis.

Authors:  Khaled Elsayad; Michael Oertel; Uwe Haverkamp; Hans Theodor Eich
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-16       Impact factor: 4.553

3.  Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides.

Authors:  M Kinoshita-Ise; T Ouchi; E Izumi; O Kawaguchi; K Nagao; M Amagai; T Funakoshi
Journal:  Clin Exp Dermatol       Date:  2017-12-21       Impact factor: 3.470

4.  Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy.

Authors:  Shamir Geller; Ken Pitter; Alison Moskowitz; Steven M Horwitz; Joachim Yahalom; Patricia L Myskowski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-05-04

Review 5.  [Treatment of indolent cutaneous B‑cell lymphoma].

Authors:  M Wobser
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

6.  Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.

Authors:  Wen-Kai Weng; Sally Arai; Andrew Rezvani; Laura Johnston; Robert Lowsky; David Miklos; Judith Shizuru; Lori Muffly; Everett Meyer; Robert S Negrin; Erica Wang; Timothy Almazan; Lynn Million; Michael Khodadoust; Shufeng Li; Richard T Hoppe; Youn H Kim
Journal:  Blood Adv       Date:  2020-09-22

7.  Total skin electron beam therapy for primary cutaneous T-cell lymphomas: clinical characteristics and outcomes in a Mexican reference center.

Authors:  Ch Flores-Balcázar; D M Urías-Arce; Y Charli-Joseph; M A De León-Alfaro; S I Pérez-Álvarez; R Ramos-Prudencio
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

8.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

9.  De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma.

Authors:  Michael Oertel; Khaled Elsayad; Carsten Weishaupt; Kerstin Steinbrink; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2019-11-22       Impact factor: 3.621

10.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.